NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 97

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated June 29, 2018.	4. Expiration Date: June 30, 2024
1. Lawrence & Memorial Hospital		5. Docket No.: 030-01275 Reference No.:
2. 365 Montauk Avenue New London, CT 06320-4769	3. License number: 06-09261-01 is amended in its entirety to read as follows:	

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 500 millicuries total	C. For any use permitted by 10 CFR 35.300, for which the patient can be released under the provisions of 10 CFR 35.75.
D. Any byproduct material permitted by 10 CFR 35.500	D. Sealed Sources (AEA Technology, Model GD.LIN2; Isotope Products Laboratories, Model NES-8426, or A-3410)	D. 120 millicuries per source and 300 millicuries total	D. For diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered in accordance with 10 CFR 30.32(g).

MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 06-09261-01	Docket or Reference Number 030-01275
	Amendment No. 97	

CONDITIONS

10. A. Licensed material may be used or stored only at the licensee's facilities located at 365 Montauk Avenue, New London, Connecticut.

    B. Licensed material in Item 6.B. may be used or stored only at the licensee's facilities located at 196 Parkway South, Suite 102, Waterford, Connecticut.

11. The Radiation Safety Officer (RSO) for this license is Michael W. Lairmore, M.S.

12. Licensed material shall only be used by, or under the supervision of:

    A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

    B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)	Material and Use
Charles W. Andrias, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.500
Roshanak Bagheri, M.D.	10 CFR 35.200
Arun Basu, M.D.	10 CFR 35.100,10 CFR 35.200; Oral administration of sodium iodide I-131; Parenteral administration of any beta emitter, or photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required
Todd Blue, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300,10 CFR 35.500
David Brill, M.D.	10 CFR 35.200
Herman Coleman, M.D.	10 CFR 35.100,10 CFR 35.200
Jon Gaudio, M.D.	10 CFR 35.200,10 CFR 35.500
Preston R. Lamberton, M.D.	10 CFR 35.300

MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 06-09261-01	Docket or Reference Number 030-01275
	Amendment No. 97	

Authorized User(M.D.,D.O.,etc.)	Material and Use
Thomas J. Manning, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 except oral administration of greater than 33 millicuries of sodium iodide I-131, 10 CFR 35.500
Francis J. Mirecki, M.D.	10 CFR 35.200,10 CFR 35.500
Valerie Popkin, M.D.	10 CFR 35.200,10 CFR 35.500
Pradnya Prakash-Velankar, M.D.	10 CFR 35.200
Sheldon Robbins, M.D.	10 CFR 35.100, 10 CFR 35.200, Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries, 10 CFR 35.500
Ira Sitko, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.500
Mark J. Somers, M.D.	10 CFR 35.200,10 CFR 35.500
John Sorrentino, M.D.	10 CFR 35.100,10 CFR 35.200; Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 06-09261-01	Docket or Reference Number 030-01275
	Amendment No. 97	

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated January 17, 2014 [ML14041A300]
B. Letter dated April 21, 2014 [ML14126A387]
C. Letter dated May 22, 2014 [ML14160A550]
D. Letter dated August 24, 2018

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: August 30, 2018

By: Janice Nguyen

Janice Nguyen
Region 1